Skip to main content
. 2010 Feb 9;95(8):1381–1388. doi: 10.3324/haematol.2009.021121

Figure 4.

Figure 4.

Influence of KIR ligand expression on event free survival (EFS) and relapse probability. The first three panels show the influence of KIR ligand expression on event free survival. (A) Event free survival (EFS) of patients with malignant diseases transplanted with CD3/CD19 depleted haploidentical grafts between 12/2003 and 12/2007 (n=50; n=15 for the “C1/C1” group and n=35 for the “not C1/C1” group). (B) EFS of patients with acute leukemias and advanced myelodysplastic syndromes (MDS) irrespective of remission status (CR and NR, n=32; n=9 for the “C1/C1” group and n = 23 for the “not C1/C1” group). (C) EFS of patients with acute leukemias/MDS in any complete remission prior to SCT (n=19; n=3 for the “C1/C1” group and n = 16 for the “not C1/C1” group). Patients homozygous for C1-alleles (dotted line) showed significantly worse survival compared to patients not homozygous for C1-alleles (solid line). The following panels show the influence of KIR ligand expression on cumulative incidence (CI) of relapse. (D) Patients with acute leukemias irrespective of remission status [CR and NR, patient numbers see (B)]. (E) Patients with acute leukemias in any complete remission prior SCT [patient numbers see (C)]. All subgroups showed a lower relapse probability for patients not homozygous for C1-alleles.